I found this interesting and can't recall reading anything about it before.
Abbott Announces New Products, Data and Positive Initiatives at 2007 AACC Annual Meeting on July 15th-19th
“We are very pleased about the future of Abbott's diagnostic business, including our core laboratory, molecular and point of care organizations”
Expanding on its growing leadership position in the diagnostics market, Abbott today announced several new product launches and initiatives at the American Association of Clinical Chemistry Annual Meeting,
Abbott Presence At AACC
Abbott has a significant presence at the four-day meeting. Abbott Diagnostics is highlighting the strengthening of its assay offerings in the metabolic, transplant, infectious disease and cardiac disease categories by showcasing 40 assays and reagents that are new to the market or under late- stage development for release. Abbott Diagnostics also is previewing 12 new systems and solutions in its pipeline of analyzers, including the ARCHITECT(R) c4000(R), ci4100(R), c16000(R), ci16200(R) and i1000SR(R). These products, which will enable greater flexibility for clinical laboratories that have low- to high-volume needs, are expected to be introduced throughout the second half of 2007, 2008 and early 2009.
Abbott Molecular is showcasing its m2000(TM) automated instrument system and the Abbott RealTime HIV-1 assay, designed to detect and precisely measure levels of the human immunodeficiency virus (HIV) circulating in a patient's blood (viral load), including the three major groups of HIV-1 as well as non-B subtypes. The test is intended for use as a marker of disease prognosis and an aid in assessing viral response to antiretroviral treatment.
Abbott Point of Care is featuring its industry leading i-STAT(R) system, which provides trusted results and a comprehensive menu for point of care, including: critical care chemistries, coagulation tests and lactate, as well as recently introduced cardiac tests including Troponin, CK-MB and BNP.
